Analyst Price Targets — TBPH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 4, 2026 7:11 am | Mayank Mamtani | B.Riley Financial | $14.00 | $13.96 | StreetInsider | B.Riley Downgrades Theravance Biopharma (TBPH) to Neutral |
| December 3, 2025 11:16 am | — | Oppenheimer | $27.00 | $18.43 | TheFly | Theravance Biopharma initiated with an Outperform at Oppenheimer |
| November 26, 2025 12:14 pm | — | BTIG | $40.00 | $18.94 | TheFly | Theravance Biopharma price target raised to $40 from $25 at BTIG |
| November 13, 2024 2:39 pm | David Risinger | Leerink Partners | $10.00 | $7.66 | StreetInsider | Leerink Partners Reiterates Market Perform Rating on Theravance Biopharma (TBPH) |
| August 6, 2024 6:08 am | Douglas Tsao | H.C. Wainwright | $15.00 | $9.59 | TheFly | Theravance Biopharma price target lowered to $15 from $20 at H.C. Wainwright |
| April 12, 2024 6:36 am | Julian Harrison | BTIG | $21.00 | $8.93 | StreetInsider | BTIG Starts Theravance Biopharma (TBPH) at Buy |
| November 17, 2022 6:03 am | — | Leerink Partners | $14.00 | $11.22 | Benzinga | SVB Leerink Maintains Outperform on Theravance Biopharma, Raises Price Target to $14 |
Latest News for TBPH
TBPH shares sink in three months after its lead drug fails a late-stage study, forcing a pipeline overhaul and raising uncertainty over its future direction.
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Theravance Biopharma Told Investors R&D Costs Were Declining Following Completion of CYPRESS Enrollment NEW YORK, April 15, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% of their investment on March 3, 2026, when the Company disclosed that its Phase 3 CYPRESS trial failed. Shareholders who lost money are encouraged to submit their information now.
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or the “Company”) (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TBPH.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.